ARCHIVES

Clinical Research; Duke Received Several Warnings from OPRR, Letters Indicate

This article is from The Cancer Letter archive.

Vol. 25 No. 19 | May 14, 1999

Download PDF Visit The Full Archive

Related Articles

Motesanib Does Not Improve OS; Study Doesn’t Meet Primary Endpoint

April 29, 2011

NCI Cooperative Group Clinical Trials Approved

May 29, 2009

NTP Committee Accepts Industry Positions On Policy To Separate Figures for Benign, Malignant Lesions

November 7, 1980

In Brief: Sporn Wins BMS Cancer Research Award; Dana-Farber To Try To Affect Teen Health

April 3, 1998

No Interest Seen Yet In Specialized Centers For Environmental Carcinogenesis

September 26, 1975

No Controversy Over Cancer Act This Time

May 25, 1990